- Home
- MIRA vs LPCN Comparison
MIRA vs LPCN Comparison
Compare MIRA & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- LPCN
- Stock Information
- Founded
- MIRA 2020
- LPCN 1997
- Country
- MIRA United States
- LPCN United States
- Employees
- MIRA N/A
- LPCN N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- LPCN Health Care
- Exchange
- MIRA Nasdaq
- LPCN Nasdaq
- Market Cap
- MIRA 19.5M
- LPCN 16.1M
- IPO Year
- MIRA 2023
- LPCN N/A
- Fundamental
- Price
- MIRA $1.21
- LPCN $3.29
- Analyst Decision
- MIRA Strong Buy
- LPCN Strong Buy
- Analyst Count
- MIRA 2
- LPCN 2
- Target Price
- MIRA $14.00
- LPCN $9.00
- AVG Volume (30 Days)
- MIRA 185.1K
- LPCN 61.0K
- Earning Date
- MIRA 08-12-2025
- LPCN 08-07-2025
- Dividend Yield
- MIRA N/A
- LPCN N/A
- EPS Growth
- MIRA N/A
- LPCN N/A
- EPS
- MIRA N/A
- LPCN N/A
- Revenue
- MIRA N/A
- LPCN $3,674,834.00
- Revenue This Year
- MIRA N/A
- LPCN N/A
- Revenue Next Year
- MIRA N/A
- LPCN N/A
- P/E Ratio
- MIRA N/A
- LPCN N/A
- Revenue Growth
- MIRA N/A
- LPCN N/A
- 52 Week Low
- MIRA $0.51
- LPCN $2.68
- 52 Week High
- MIRA $5.01
- LPCN $8.71
- Technical
- Relative Strength Index (RSI)
- MIRA 46.79
- LPCN 51.52
- Support Level
- MIRA $1.21
- LPCN $3.13
- Resistance Level
- MIRA $1.30
- LPCN $3.53
- Average True Range (ATR)
- MIRA 0.08
- LPCN 0.24
- MACD
- MIRA -0.01
- LPCN 0.01
- Stochastic Oscillator
- MIRA 31.58
- LPCN 48.33
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.